Pharmacogenomic screening for agranulocytosis and efficacy with clozapine

Abstract

Aim: To review genetic biomarkers of agranulocytosis and efficacy with clozapine as a screening tool for the safe and effective use of clozapine.

Methods: A PubMed search was performed using PRISMA guidelines for English articles. Separate searches were conducted using “clozapine” AND “agranulocytosis,” and “clozapine” AND (“response” OR efficacy “outcome”) AND “schizophrenia”. Eligible studies reported positive findings with genetic polymorphism(s) associated with clozapine-induced agranulocytosis (CIA) and clozapine’s efficacy. Case reports/series, abstracts, systematic reviews, and meta-analyses were excluded. Negative and genome-wide studies were not formally reviewed but included in the discussion.

Results: Twelve out of 572 CIA studies and 32 out of 126 efficacy studies met the eligibility criteria for this review. Most reviewed studies were conducted in small samples of Jewish, Caucasian, and Asian populations using a candidate gene approach.

Conclusion: Future research needs to address the limitations of the findings from the reviewed studies to enable a combined genetic screening for CIA and clozapine response to optimize the safe and effective use of clozapine without unnecessarily exposing potential clozapine nonresponders to CIA or neutropenia.

Keywords

Pharmacogenomic / screening / clozapine / efficacy / agranulocytosis

References

[1] Schizophrenia. Fact sheet on schizophrenia: key facts, symptoms, causes of schizophrenia, WHO; 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia [Last accessed on 15 June 2023].

[2] KaneJM,BaldwinML.Clinical guidance on the identification and management of treatment-resistant schizophrenia.J Clin Psychiatry2019;80:18com12123

[3] HowesOD,GeeS,KapurS.Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation.Br J Psychiatry2012;201:481-5

[4] GörenJL,SmithEG.The business case for expanded clozapine utilization.Psychiatr Serv2016;67:1197-205

[5] ErtugrulA.Clozapine and suicide.Am J Psychiatry2002;159:323

[6] ErnstCL.Antisuicide properties of psychotropic drugs: a critical review.Harv Rev Psychiatry2004;12:14-41

[7] VermaM,ChakrabartiS.Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia.Nord J Psychiatry2021;75:135-44

[8] ThienK.Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review.Early Interv Psychiatry2019;13:18-23

[9] WhiskeyE,OloyedeE,TaylorDM.An evaluation of the variation and underuse of clozapine in the United Kingdom.Acta Psychiatr Scand2021;143:339-47

[10] BogersJP,VanDijk D,CohenD.Clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates be improved?.J Clin Psychopharmacol2016;36:109-11

[11] WarnezS.Clozapine: a review of clinical practice guidelines and prescribing trends.BMC Psychiatry2014;14:102 PMCID:PMC3999500

[12] VerdouxH,BachmannCJ.Prescriber and institutional barriers and facilitators of clozapine use: a systematic review.Schizophr Res2018;201:10-9

[13] VerdouxH.Educational needs and psychoeducation interventions in clozapine users: a narrative review.Acta Psychiatr Scand2020;142:96-108

[14] WahlbeckK,EssaliA.Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.Am J Psychiatry1999;156:990-9

[15] BaigAI,EbrahimG.Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: a systematic review.Medicine2021;100:e27694

[16] WasermanJ.Subjective experiences of clozapine treatment by patients with chronic schizophrenia.Psychiatr Serv2000;51:666-8

[17] CitromeL,SakladSR.Guide to the management of clozapine-related tolerability and safety concerns.Clin Schizophr Relat Psychoses2016;10:163-77

[18] ChathothV,SolomonS.Clozapine-induced insulin-resistant hyperglycemia in a diabetic patient.Indian J Psychol Med2018;40:375-7 PMCID:PMC6065131

[19] MylesN,XiaS.Meta-analysis examining the epidemiology of clozapine-associated neutropenia.Acta Psychiatr Scand2018;138:101-9

[20] LiXH,LuL.The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies.Psychol Med2020;50:583-94

[21] Leon J, Sanz EJ, De Las Cuevas C. Data from the world health organization’s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions.Schizophr Bull2020;46:1-3 PMCID:PMC6942151

[22] MeltzerHY.Clozapine: balancing safety with superior antipsychotic efficacy.Clin Schizophr Relat Psychoses2012;6:134-44

[23] FarooqS.Clozapine: dangerous orphan or neglected friend?.Br J Psychiatry2011;198:247-9

[24] FarooqS,CohenD,AyubM.Barriers to using clozapine in treatment-resistant schizophrenia: systematic review.BJPsych Bull2019;43:8-16 PMCID:PMC6327301

[25] GeeS,HowesO.Practitioner attitudes to clozapine initiation.Acta Psychiatr Scand2014;130:16-24

[26] ShahP,PlitmanE.The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review.Psychiatry Res2018;268:114-22

[27] SchulteP.Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.Ann Pharmacother2006;40:683-8

[28] GirardinFR,BlondonM.Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis.Lancet Psychiatry2014;1:55-62

[29] FabrazzoM,SampognaG.Clozapine versus other antipsychotics during the first 18 weeks of treatment: A retrospective study on risk factor increase of blood dyscrasias.Psychiatry Res2017;256:275-82

[30] ÜçokA,KarabulutS.Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia.Int Clin Psychopharmacol2015;30:290-5

[31] JohnAP,DominicA.Delayed initiation of clozapine continues to be a substantial clinical concern.Can J Psychiatry2018;63:526-31 PMCID:PMC6099752

[32] VargheseM T,ShajiKS.Delaying clozapine: how long is too long?.Gen Psychiatr2020;33:e100172 PMCID:PMC7213869

[33] VerbelenM.How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?.Pharmacogenomics2015;16:915-7

[34] SiskindD,KiselyS.Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis.Can J Psychiatry2017;62:772-7 PMCID:PMC5697625

[35] ShahP,BrownEE.Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.Eur Arch Psychiatry Clin Neurosci2020;270:11-22

[36] MeltzerHY.Treatment-resistant schizophrenia-the role of clozapine.Curr Med Res Opin1997;14:1-20

[37] MoherD,TetzlaffJ.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.PLoS Med2009;6:e1000097 PMCID:PMC2707599

[38] IslamF,LewisD.Pharmacogenomics of clozapine-induced agranulocytosis: a systematic review and meta-analysis.Pharmacogenomics J2022;22:230-40 PMCID:PMC9363274

[39] LiebermanJA,EgeaE,KaneJM.HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia.Arch Gen Psychiatry1990;47:945-8

[40] CorzoD,SalazarM.The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups.Blood1995;86:3835-40

[41] YunisJJ,SalazarM,HowardA.HLA associations in clozapine-induced agranulocytosis.Blood1995;86:1177-83

[42] TurbayD,AlperCA.Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups.Blood1997;89:4167-74

[43] AmarA,ShtrussbergS.An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201.Int J Neuropsychopharmacol1998;1:41-4

[44] ValevskiA,GazitE.HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients.Eur J Immunogenet1998;25:11-3

[45] OstrouskyO,LoewenthalR.NQO2 gene is associated with clozapine-induced agranulocytosis.Tissue Antigens2003;62:483-91

[46] LahdelmaL,AnderssonLC.Mitchell B. Balter award. human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia.J Clin Psychopharmacol2001;21:4-7

[47] DettlingM,Mueller-OerlinghausenB,CascorbiI.Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry.Pharmacogenetics2001;11:135-41

[48] DettlingM,Opgen-RheinC.Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens.Pharmacogenomics J2007;7:325-32

[49] vander Weide K,PondmanK.Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.Pharmacogenomics J2017;17:471-8

[50] AthanasiouMC,CascorbiI.Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis.J Clin Psychiatry2011;72:458-63

[51] LeggeSE,RipkeS.Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia.Mol Psychiatry2017;22:1502-8 PMCID:PMC5065090

[52] GoldsteinJI,HilliardC.Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles.Nat Commun2014;5:4757 PMCID:PMC4155508

[53] SaitoT,MushirodaT.Pharmacogenomic study of clozapine-induced agranulocytosis/granulocytopenia in a Japanese population.Biol Psychiatry2016;80:636-42

[54] EapCB,SirotEJ.Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.J Clin Psychopharmacol2004;24:214-9

[55] BalibeyH,LundgrenS.CYP1A2*1F polymorphism decreases clinical response to clozapine in patients with schizophrenia.Bull Clin Psychopharm2011;21:93-9

[56] deBrito RB,DinizMJA.The CYP1A2 -163C > A polymorphism is associated with super-refractory schizophrenia.Schizophr Res2015;169:502-3

[57] PiatkovI,AssurY.CYP2C19*17 protects against metabolic complications of clozapine treatment.World J Biol Psychiatry2017;18:521-7

[58] LeeST,KimSR.Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.J Clin Psychopharmacol2012;32:441-8

[59] ShaikhS,ShamPC.Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia.Hum Genet1996;97:714-9

[60] ScharfetterJ,HornikK.Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients.Eur Neuropsychopharmacol1999;10:17-20

[61] HwangR,TiwariA.Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant.Pharmacogenomics J2010;10:200-18

[62] HuangE,ZaiCC.Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.Pharmacogenomics2016;17:103-9

[63] HwangR,DelucaV.Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment.Eur Neuropsychopharmacol2006;16:248-59

[64] HwangR,DeLuca V.Association study of 12 polymorphisms spanning the dopamine D₂ receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.Psychopharmacology2005;181:179-87

[65] MalhotraA. Allelic variation in the promoter region of the dopamine D-2 receptor gene and clozapine response. In: Schizophrenia research. Amsterdam, Netherlands: Elsevier Science B.V.; 1999.

[66] HwangR,ZaiCC.Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration.Prog Neuropsychopharmacol Biol Psychiatry2012;37:62-75

[67] ZhaoAL,ZhangYH,LiuZN.[Distribution of genotype and allele frequencies of dopamine D4 receptor gene 48 bp variable number tandem repeat polymorphism in Chinese Han population in Hunan].Zhonghua Yi Xue Yi Chuan Xue Za Zhi2005;22:470-2

[68] HwangR,DeLuca V.Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response.J Psychopharmacol2007;21:718-27

[69] PotkinSG,JinY.D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine.Mol Psychiatry2003;8:109-13

[70] WoodwardND,MeltzerHY.COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.Schizophr Res2007;90:86-96

[71] XuM,LiS.Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry2010;34:1026-32

[72] ArranzMJ,MunroJ.Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.Neurosci Lett1996;217:177-8

[73] ArranzMJ,OwenMJ.Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.Mol Psychiatry1998;3:61-6

[74] MasellisM,MeltzerHY.Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.Neuropsychopharmacology1998;19:123-32

[75] ArranzM,SodhiM.Association between clozapine response and allelic variation in 5-HT2A receptor gene.Lancet1995;346:281-2

[76] SouzaRP,MeltzerHY,KennedyJL.Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia.Pharmacogenet Genomics2010;20:274-6

[77] RajkumarAP,KuruvillaA,JacobM.Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.Psychopharmacology2012;224:441-9

[78] KohlrauschFB,GamaCS,Belmonte-de-AbreuP.Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics.J Psychiatr Res2010;44:1158-62

[79] YuYW,LinCH,YangKH.Serotonin-6 receptor variant (C267T) and clinical response to clozapine.Neuroreport1999;10:1231-3

[80] SodhiMS,CurtisD.Association between clozapine response and allelic variation in the 5-HT2C receptor gene.Neuroreport1995;7:169-72

[81] ArranzMJ,BirkettJ.Pharmacogenetic prediction of clozapine response.Lancet2000;355:1615-6

[82] HwangR,TiwariAK.Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response.Pharmacogenomics2011;12:277-91

[83] BosiaM,PirovanoA.COMT Val158Met and 5-HT1A-R-1019 C/G polymorphisms: effects on the negative symptom response to clozapine.Pharmacogenomics2015;16:35-44

[84] RajagopalVM,JacobKS.Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia.Pharmacogenet Genomics2018;28:31-5

[85] XuM.Genetic influences of dopamine transport gene on alcohol dependence: a pooled analysis of 13 studies with 2483 cases and 1753 controls.Prog Neuropsychopharmacol Biol Psychiatry2011;35:1255-60 PMCID:PMC5335908

[86] YuYW,YangKH,ChenMC.Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine.Neuropsychobiology2001;43:79-82

[87] BrandlEJ,ChowdhuryNI.The role of the ITIH3 rs2535629 variant in antipsychotic response.Schizophr Res2016;176:131-5

[88] IkedaM,HashimotoR.Genetic overlap between antipsychotic response and susceptibility to schizophrenia.J Clin Psychopharmacol2015;35:85-8

[89] AdkinsDE,McClayJL.Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.Mol Psychiatry2011;16:321-32 PMCID:PMC2891163

[90] With SAJ, Pulit SL, Staal WG, Kahn RS, Ophoff RA. More than 25 years of genetic studies of clozapine-induced agranulocytosis.Pharmacogenomics J2017;17:304-11

[91] LallyJ,WhiskeyE.Clozapine-associated agranulocytosis treatment with granulocyte colony-stimulating factor/granulocyte-macrophage colony-stimulating factor: a systematic review.J Clin Psychopharmacol2017;37:441-6

[92] la Chapelle A, Kari C, Nurminen M, Hernberg S. Clozapine-induced agranulocytosis. A genetic and epidemiologic study.Hum Genet1977;37:183-94

[93] AmslerHA,BarthE,VuopioP.Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic.Acta Psychiatr Scand1977;56:241-8

[94] ClarkSR,KimG.Elevated clozapine levels associated with infection: a systematic review.Schizophr Res2018;192:50-6

[95] RuanCJ,GeXL.Pneumonia can cause clozapine intoxication: a case report.Psychosomatics2017;58:652-6

[96] WagnerA.Relationship between clozapine levels and acute inflammatory stress.Prim Care Companion CNS Disord2020;22:19br02586

[97] RaaskaK.Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia.Eur J Clin Pharmacol2000;56:585-9

[98] PriorTI.Interactions between the cytochrome P450 system and the second-generation antipsychotics.J Psychiatry Neurosci2003;28:99-112 PMCID:PMC161731

[99] RuanCJ.Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?.Pharmacogenomics2020;21:369-73

[100] Buur-RasmussenB.Cytochrome P450 and therapeutic drug monitoring with respect to clozapine.Eur Neuropsychopharmacol1999;9:453-9

[101] DettlingM,Müller-OerlinghausenB.Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6.Pharmacopsychiatry2000;33:218-20

[102] RøgeR,AndersenCR,NielsenJ.Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far?.Schizophr Res2012;140:204-13

[103] TaylorD,WhiskeyE,MacCabeJ.Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis.Schizophrenia2022;8:21 PMCID:PMC8920060

[104] MunroJ,AndrewsC,MortimerA.Active monitoring of 12760 clozapine recipients in the UK and Ireland.Br J Psychiatry1999;175:576-80

[105] Riecher-RösslerA.[50 years after Manfred Bleuler. what do we know today about late-onset schizophrenia(s)?].Nervenarzt1997;68:159-70

[106] DettlingM,RootsI.Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample.Arch Gen Psychiatry2001;58:93-4

[107] Deliliers G. Blood dyscrasias in clozapine-treated patients in Italy.Haematologica2000;85:233-7

[108] StübnerS,EngelR.Blood dyscrasias induced by psychotropic drugs.Pharmacopsychiatry2004;37 Suppl 1:S70-8

[109] DemlerTL,MeyerCE.Maximizing clozapine utilization while minimizing blood dyscrasias: evaluation of patient demographics and severity of events.Int Clin Psychopharmacol2016;31:76-83

[110] HollingworthSA,SaiepourN,MylesN.Correction to: clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014.Psychopharmacology2018;235:2193

[111] TunsirimasN,ChoovanichvongS.Clozapine-induced agranulocytosis and leukopenia: incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand.Asian J Psychiatr2019;41:13-6

[112] AlvirJM,SaffermanAZ,SchaafJA.Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.N Engl J Med1993;329:162-7

[113] WellesleyWesley E,Kadra-ScalzoG.Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register.Schizophr Res2021;232:68-76

[114] HoráčekJ,HöschlC,HendrychováI.Clozapine-induced concordant agranulocytosis in monozygotic twins.Int J Psychiatry Clin Pract2001;5:71-3

[115] Yağcıoğlu AE, İlhan BÇ, Göktaş MT, Babaoğlu MO, Uz E, Yazıcı MK. Agranulocytosis related to clozapine in monozygotic twins and association with allelic variants of multidrug resistance gene MDR1.J Clin Psychopharmacol2011;31:247-9

[116] Osafo-AddoAD,OduroAR,HodgsonA.HLA-DRB1*04 allele is associated with severe malaria in northern Ghana.Am J Trop Med Hyg2008;78:251-5

[117] ParkHW,KimSH.Efficacy of the HLA-B*58:01 screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency-a prospective study.J Allergy Clin Immunol Pract2019;7:1271-6

[118] WangQ,XieM,LiX.Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: a meta-analysis.Epilepsy Res2017;135:19-28

[119] HughesAR,BansalAT.Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.Pharmacogenomics2004;5:203-11

[120] CapuleF,MahasirimongkolS.Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients.Pharmacogenomics J2020;20:533-41

[121] VerbelenM,CohenD,LewisCM.Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis.Pharmacogenomics J2015;15:461-6 PMCID:PMC4762904

[122] GroverS.HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis.Pharmacogenet Genomics2014;24:94-112

[123] MijovicA.Clozapine-induced agranulocytosis.Ann Hematol2020;99:2477-82 PMCID:PMC7536144

[124] KonteB,RujescuD.HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry.Transl Psychiatry2021;11:214 PMCID:PMC8042025

[125] SaitoT,HashimotoR.Transethnic replication study to assess the association between clozapine-induced agranulocytosis/granulocytopenia and genes at 12p12.2 in a Japanese population.Biol Psychiatry2017;82:e9-10

[126] ChenJ,ZhangQ.Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study.Transl Psychiatry2021;11:343 PMCID:PMC8175348

[127] MosyaginI,RootsI,CascorbiI.Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis.J Clin Psychopharmacol2004;24:613-7

[128] LeggeSE,HelthuisM.A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia.Mol Psychiatry2019;24:328-37

[129] Okhuijsen-PfeiferC,HornIM,KahnRS.Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis.Neurosci Biobehav Rev2020;111:246-52

[130] ComacchioC,LasalviaA.Successful use of single doses of granulocyte-colony stimulating factor (G-CSF) in the treatment of late-onset agranulocytosis associated with clozapine in a patient with treatment-resistant schizophrenia: a case report.J Clin Psychopharmacol2016;36:173-4

[131] FreemanGM Jr,HuRJ.G-CSF dosing to prevent recurrent clozapine-induced agranulocytosis.Am J Psychiatry2016;173:643

[132] LallyJ,KrivoyA.The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review.J Clin Psychopharmacol2017;37:600-4

[133] BlierP,MeashamT,WiviottG.Lithium and clozapine-induced neutropenia/agranulocytosis.Int Clin Psychopharmacol1998;13:137-40

[134] ArranzMJ.Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.Mol Psychiatry2007;12:707-47

[135] ShadMU.Clozapine toxicity: a discussion of pharmacokinetic factors.Asian J Psychiatr2008;1:47-9

[136] ShadMU,RoyK.How to identify and manage non-response to clozapine?.Asian J Psychiatr2019;45:50-2

[137] UrichukL,DursunS.Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.Curr Drug Metab2008;9:410-8

[138] KroonLA.Drug interactions with smoking.Am J Health Syst Pharm2007;64:1917-21

[139] RajkumarAP,KuruvillaA,JacobM.Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia.Acta Neuropsychiatr2013;25:2-11

[140] PiatkovI,AssurY.ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine.Pharmgenomics Pers Med2017;10:235-42 PMCID:PMC5587196

[141] XingQ,LiH.Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.Pharmacogenomics2006;7:987-93

[142] ZhaoAL,ZhangYH,ChenJD.Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine.Int J Neurosci2005;115:1539-47

[143] ZhangJP,MalhotraAK.D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.Am J Psychiatry2010;167:763-72 PMCID:PMC2896457

[144] GressierF,CalatiR.Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis.Eur Neuropsychopharmacol2016;26:163-85

[145] SchäferM,GieglingI.Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D₂ receptor gene.Am J Psychiatry2001;158:802-4

[146] SuzukiA,OtaniK.Association of the TaqI A polymorphism of the dopamine D₂ receptor gene with predisposition to neuroleptic malignant syndrome.Am J Psychiatry2001;158:1714-6

[147] VijayanNN,KoshyLV.Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population.Behav Brain Funct2007;3:34 PMCID:PMC1947997

[148] DahmenN,GermeyerS.Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients.Schizophr Res2001;49:223-5

[149] SamanaiteR,SendtKV,MacCabeJH.Biological predictors of clozapine response: a systematic review.Front Psychiatry2018;9:327 PMCID:PMC6070624

[150] NumataS,OhmoriT.Clozapine pharmacogenetic studies in schizophrenia: efficacy and agranulocytosis.Front Pharmacol2018;9:1049 PMCID:PMC6169204

[151] AnttilaS,KampmanO,LehtimäkiT.Interaction between NOTCH₄ and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics.Pharmacogenetics2004;14:303-7

[152] HuangE,LisowayA.Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis.Int J Neuropsychopharmacol2016;19:pyv132 PMCID:PMC4886669

[153] MoleroP,ZalacainM.Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.Pharmacogenomics J2007;7:418-26

[154] WeickertTW,MisharaA.Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications.Biol Psychiatry2004;56:677-82

[155] SzekeresG,JuhászA.Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.Am J Med Genet B Neuropsychiatr Genet2004;124B:1-5

[156] MeltzerHY.An overview of the mechanism of action of clozapine.J Clin Psychiatry1994;55 Suppl B:47-52

[157] ArranzMJ,ShamP.Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.Schizophr Res1998;32:93-9

[158] JooberR,BriseboisK.T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability.J Psychiatry Neurosci1999;24:141-6 PMCID:PMC1188995

[159] ArranzMJ,MunroJ.Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response.Pharmacogenetics1998;8:481-4

[160] HamdaniN,AdèsJ,BoniC.Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics.Neurosci Lett2005;377:69-74

[161] BenmessaoudD,BoniC.Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics.BMC Psychiatry2008;8:40 PMCID:PMC2426688

[162] MauriMC,MaffiniM.Clinical pharmacology of atypical antipsychotics: an update.EXCLI J2014;13:1163-91 PMCID:PMC4464358

[163] BirkettJT,MunroJ,KerwinRW.Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response.Neuroreport2000;11:2017-20

[164] GutiérrezB,Huezo-DiazP.Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response.Schizophr Res2002;58:93-7

[165] WangL,ZhangA.The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.J Psychopharmacol2008;22:904-9

[166] ReynoldsGP,TemplemanLA,SanL.Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients.Am J Psychiatry2006;163:1826-9

[167] MössnerR,KühnKU.Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.Pharmacogenet Genomics2009;19:91-4

[168] MasellisM,MeltzerHY.Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia.Schizophr Res2001;47:49-58

[169] SchumacherJ,WienkerTF,NöthenMM.Pharmacogenetics of the clozapine response.Lancet2000;356:506-7

[170] TsaiSJ,YuYW.Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response.Schizophr Res2000;44:177-81

[171] ArranzMJ,MunroJ,CollierDA.The serotonin transporter and clozapine response.Mol Psychiatry2000;5:124-5

[172] LeeHY,LeeHJ,KimYK.No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients.Prog Neuropsychopharmacol Biol Psychiatry2009;33:276-80

[173] Vázquez-BourgonJ,MataI.Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis.Psychiatry Res2010;175:189-94

[174] XuQ,LiM.Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.Pharmacogenomics J2016;16:357-65

[175] RuderferDM,ReadheadB.Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.Lancet Psychiatry2016;3:350-7 PMCID:PMC4982509

[176] GardnerKR,ScottR.The potential utility of pharmacogenetic testing in psychiatry.Psychiatry J2014;2014:730956 PMCID:PMC4281386

[177] EumS,BishopJR.Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.Dialogues Clin Neurosci2016;18:323-37 PMCID:PMC5067149

[178] FabbriC,SerrettiA.Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials.Prog Neuropsychopharmacol Biol Psychiatry2018;86:36-44